Biosimilars, social media among 2015 expected FDA guidances
This article was originally published in Scrip
Executive Summary
The FDA on 6 January issued its agenda, without specific dates, for new and revised draft guidances expected to be issued in 2015 by the Center for Drug Evaluation and Research (CDER), including the much anticipated documents affecting biosimilar products and drug makers' use of social media.